Literature DB >> 15014904

Relationship of 99mTc-HYNIC annexin V uptake to microvessel density, FasL and MMP-9 expression, and the number of tumour-infiltrating lymphocytes in head and neck carcinoma.

Hubert Vermeersch1, Kris Mervillie, Christophe Lahorte, David Loose, Rudi Andre Dierck, Neil Steinmetz, Claude Cuvelier, Guido Slegers, Christophe Van de Wiele.   

Abstract

This study reports on the relationship between quantitative (99m)Tc-HYNIC radiolabelled annexin V tumour uptake measurements, Fas ligand (FasL) expression, matrix metalloproteinase-9 (MMP-9) expression, microvessel density (MVD) and the number of tumour-infiltrating lymphocytes in squamous cell carcinoma of the head and neck (SCCHN) patients. Twenty-eight patients (24 men and 4 women; mean age 59 years, range 43-83 years) suffering from a primary ( n, number of patients=22) or locally recurrent ( n=6) SCCHN were studied. All patients underwent a spiral CT scan, allowing estimation of lesion size in three dimensions, and (99m)Tc-HYNIC annexin V scintigraphy within 1 week of each other. Biopsies or resection of the suspected primary tumour or local recurrence for histopathological analysis were performed on all patients within a period of 10 days following (99m)Tc-HYNIC annexin V scintigraphy. The percentage uptake of the injected dose of (99m)Tc-HYNIC annexin V in visible tumour lesions on scintigrams divided by the tumour volume, derived from CT, was related to MVD and to histological score (HSCORE) values for MMP-9 and FasL expression as well as to the number of tumour-infiltrating lymphocytes (CD45 staining). Median percentage absolute tumour uptake of the injected dose/cm(3) tumour volume derived from tomographic images was 0.0001% (SD 0.0001%) at 5-6 h p.i. (range: 0.000007-0.0003%). Mean HSCORE for MMP-9 tumour staining was 2.1 (SD 0.84). Mean HSCORE for FasL tumour staining was 2.49 (SD 0.92). At the sites of tumour containing the highest number of vessels, the mean MVD was 20 vessels/field at the hot spot (range 1-73). The median number of tumour-infiltrating lymphocytes was 500 (range 100-5,000). The percentage absolute tumour uptake of the injected dose/cm(3) tumour volume derived from tomographic images correlated linearly with FasL HSCORES( r=0.47, P=0.02). No correlation was found between the percentage absolute tumour uptake of the injected dose/cm(3) tumour volume derived from tomographic images and MMP-9 HSCORES, MVD or the number of tumour-infiltrating lymphocytes. MVD correlated significantly with MMP-9 HSCORES ( r=0.44, P=0.03).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15014904     DOI: 10.1007/s00259-004-1499-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  26 in total

1.  Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck.

Authors:  P O-Charoenrat; P H Rhys-Evans; S A Eccles
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2001-07

2.  Clinical relevance of Fas (APO-1/CD95) expression in laryngeal squamous cell carcinoma.

Authors:  M C Jäckel; C Mitteldorf; S Schweyer; L Füzesi
Journal:  Head Neck       Date:  2001-08       Impact factor: 3.147

3.  Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck.

Authors:  Alessandro Franchi; Marco Santucci; Emanuela Masini; Iacopo Sardi; Milena Paglierani; Oreste Gallo
Journal:  Cancer       Date:  2002-11-01       Impact factor: 6.860

4.  Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.

Authors:  B R Gastman; Y Atarshi; T E Reichert; T Saito; L Balkir; H Rabinowich; T L Whiteside
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

5.  Production and regulation of gelatinase B by human T-cells.

Authors:  A M Montgomery; H Sabzevari; R A Reisfeld
Journal:  Biochim Biophys Acta       Date:  1993-04-16

6.  Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy.

Authors:  Sophia Ran; Philip E Thorpe
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-12-01       Impact factor: 7.038

Review 7.  Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets.

Authors:  Pia Vihinen; Veli-Matti Kähäri
Journal:  Int J Cancer       Date:  2002-05-10       Impact factor: 7.396

8.  Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer.

Authors:  C Kuropkat; S Plehn; U Herz; A A Dünne; H Renz; J A Werner
Journal:  Anticancer Res       Date:  2002 Jul-Aug       Impact factor: 2.480

9.  Cells behaving badly: a theoretical model for the Fas/FasL system in tumour immunology.

Authors:  Steven D Webb; Jonathan A Sherratt; Reginald G Fish
Journal:  Math Biosci       Date:  2002 Sep-Oct       Impact factor: 2.144

10.  Stimulus specificity of matrix metalloproteinase dependence of human T cell migration through a model basement membrane.

Authors:  M Xia; D Leppert; S L Hauser; S P Sreedharan; P J Nelson; A M Krensky; E J Goetzl
Journal:  J Immunol       Date:  1996-01-01       Impact factor: 5.422

View more
  5 in total

Review 1.  (99m)Tc-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials.

Authors:  Tarik Z Belhocine; Francis G Blankenberg; Marina S Kartachova; Larry W Stitt; Jean-Luc Vanderheyden; Frank J P Hoebers; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-16       Impact factor: 9.236

2.  Imaging apoptosis in the eye.

Authors:  M F Cordeiro; C Migdal; P Bloom; F W Fitzke; S E Moss
Journal:  Eye (Lond)       Date:  2011-03-25       Impact factor: 3.775

Review 3.  SPECT and PET radiopharmaceuticals for molecular imaging of apoptosis: from bench to clinic.

Authors:  Xiaobo Wang; Han Feng; Shichao Zhao; Junling Xu; Xinyu Wu; Jing Cui; Ying Zhang; Yuhua Qin; Zhiguo Liu; Tang Gao; Yongju Gao; Wenbin Zeng
Journal:  Oncotarget       Date:  2017-03-21

Review 4.  Avenues to molecular imaging of dying cells: Focus on cancer.

Authors:  Anna A Rybczynska; Hendrikus H Boersma; Steven de Jong; Jourik A Gietema; Walter Noordzij; Rudi A J O Dierckx; Philip H Elsinga; Aren van Waarde
Journal:  Med Res Rev       Date:  2018-03-12       Impact factor: 12.944

Review 5.  Radionuclide imaging of apoptosis for clinical application.

Authors:  Xiyi Qin; Han Jiang; Yu Liu; Hong Zhang; Mei Tian
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-12-07       Impact factor: 9.236

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.